Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' Income towards Parent Company fell 26279.32% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 13932.5%. This contributed to the annual value of -$110.0 million for FY2024, which is 2817.25% down from last year.
  • Viking Therapeutics' Income towards Parent Company amounted to -$90.8 million in Q3 2025, which was down 26279.32% from -$65.5 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Income towards Parent Company high stood at -$12.4 million for Q4 2021, and its period low was -$90.8 million during Q3 2025.
  • Moreover, its 5-year median value for Income towards Parent Company was -$19.6 million (2022), whereas its average is -$27.4 million.
  • As far as peak fluctuations go, Viking Therapeutics' Income towards Parent Company plummeted by 1044.42% in 2023, and later crashed by 26279.32% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' Income towards Parent Company stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 156.51% to -$90.8 million in 2025.
  • Its Income towards Parent Company was -$90.8 million in Q3 2025, compared to -$65.5 million in Q2 2025 and -$45.6 million in Q1 2025.